Neurotrope To Host Conference Call - FOX 42: Omaha News, Sports and Weather; |

Neurotrope To Host Conference Call

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Neurotrope, Inc.

Will Provide Business Update on Tuesday, August 26, 2014

PLANTATION, Fla., Aug. 20, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that it will host a conference call to provide an update on Company activities.

Access information:


Tuesday, August 26, 2014


4:30 p.m. Eastern daylight time

Dial-in numbers:                     

(888) 505-4369 (U.S. and Canada) or (719) 325-2315

Conference ID number:          


Live web cast:                , under "Investor Relations"

The teleconference replay will be available from three hours after completion through September 2, 2014 at (888) 203-1112 (U.S. and Canada) or (719) 457-0820. The replay pass code is 9126599. The archived web cast will be available on the Company's web site:, under "Investor Relations."

About Neurotrope

Neurotrope was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies developed by the Blanchette Rockefeller NeuroSciences Institute (BRNI). Neurotrope's pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer's disease and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer's in patients. A Phase 2a study with bryostatin for the treatment of Alzheimer's disease is currently being conducted. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai to utilize its proprietary information and data package for the use of Bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimers' disease-like symptoms. Also, as part of its license from BRNI, the Company has the rights to pursue treatments for a number of orphan diseases, including Fragile X Syndrome. The Company's preclinical and clinical efforts are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe, which has been shown to play a central role in the regrowth or repair of nerve tissues, cells or cell products.

Please visit for further information.

For additional information, please contact:
Robert Weinstein
Chief Financial Officer
(914) 295-2765

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

General Information:

Phone: 402-554-4282
Fax: 402-554-4279

Can't find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KPTM. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.